drugset
drugset / Trial / NCT00095797

XK469R in Treating Patients With Refractory Hematologic Cancer

NCT00095797 ↗

Phase 1 Completed 60 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of XK469R in treating patients who have refractory hematologic cancer. Drugs used in chemotherapy, such XK469R, work in different ways to stop cancer cells from dividing so they stop growing or die

Timeline

Start
2004-10
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject R(+)XK469 Small molecule — Intravenous

Indications

B-cell chronic lymphocytic leukemia acute basophilic leukemia acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 adult acute monocytic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia myelodysplastic syndrome with excess blasts refractory anemia with excess blasts in transformation